Related Experiment Video
Updated: Jul 15, 2025

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction
Yongjie Bao1,2, Wenni Rong2, An Zhu2
1Department of Anesthesiology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, China.
Abstract:
Postoperative cognitive dysfunction (POCD) is a clinical syndrome characterizing by cognitive impairments in the elderly after surgery. There is limited effective treatment available or clear pathological mechanisms known for this syndrome. In this study, a Connectivity Map (CMap) bioinformatics model of POCD was established by using differently expressed landmark genes in the serum samples of POCD and non-POCD patients from the only human transcriptome study. The predictability and reliability of this model were further supported by the positive CMap scores of known POCD inducers and the negative CMap scores of anti-POCD drug candidates. Most retinoic acid receptor (RAR) agonists were negatively associated with POCD in this CMap model, suggesting that RAR might be a novel target for POCD. Most importantly, acitretin, a clinically used RAR agonist, significantly inhibited surgery-induced cognitive impairments and prevented the reduction in RARα and RARα-target genes in the hippocampal regions of aged mice. The study denotes a reliable CMap bioinformatics model of POCD for future use and establishes that RAR is a novel therapeutic target for treating this clinical syndrome.
More Related Videos
11:24Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
Published on: October 18, 2011
09:04Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies
Published on: April 22, 2017
Related Concept Videos
Alzheimer's Disease: Treatment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists